Corvus Pharmaceuticals (CRVS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
8 Nov, 2026Executive summary
Soquelitinib development spans PTCL, atopic dermatitis, hidradenitis suppurativa, asthma and ALPS, with multiple clinical milestones planned for 2027.
Phase 3 PTCL and Phase 2 SIERRA1 atopic dermatitis trials remained on track; SIERRA1 top-line data are expected in Q3 2027.
No product sales revenue has been generated.
Financial highlights
Q3 2026 R&D expense was $17.8M vs. $8.5M in Q3 2025, mainly reflecting higher soquelitinib trial and personnel costs; Q3 operating expenses were $21.4M vs. $10.6M.
Q3 2026 net loss was $20.3M vs. $10.2M; nine-month net loss was $52.0M vs. $3.0M, with the prior-year period including a $27.1M warrant fair-value gain.
Q3 net loss per share was $0.22 vs. $0.12; nine-month net loss per share was $0.57 vs. $0.04 basic and $0.38 diluted in 2025.
Q3 stock-based compensation was $2.8M vs. $1.2M; nine-month expense was $8.1M vs. $3.8M.
Nine-month operating cash use was $38.0M; investing cash use was $143.3M, including $239.9M of securities purchases and $102.3M of maturities.
Outlook and guidance
$202.9M in cash, cash equivalents and marketable securities at September 30, 2026, is expected to fund planned operations into Q2 2028.
PTCL event-driven futility analysis is expected in Q1 2027; trial readout is anticipated in late 2027/early 2028.
SIERRA1 top-line data are expected in Q3 2027; a Phase 3 start in 2028 is possible if results support advancement.
HS Phase 1b results are expected in 1H 2027; soquelitinib Phase 2 asthma trial initiation is planned for Q1 2027, enrolling T2 and non-T2 patients.
Angel Pharmaceuticals’ China atopic dermatitis cohort 1 results are expected in Q1 2027; its Phase 2 asthma trial is anticipated to start in Q2 2027.
Latest events from Corvus Pharmaceuticals
- Oral ITK inhibitor soquelitinib targets multiple immune diseases with pivotal data expected by 2027.CRVS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Soquelitinib shows robust efficacy and safety in AD, supporting broad immune disease potential.CRVS
Corporate presentation - Q2 2026 net loss rose to $18M as R&D spending increased; cash runway extends into Q2 2028.CRVS
Q2 2026 - Lead asset soquelitinib advances in oncology and immunology with strong IP and cash runway.CRVS
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Durable efficacy and safety demonstrated in immune diseases, with broad clinical expansion underway.CRVS
Jefferies Global Healthcare Conference 2026 - Soquelitinib achieved durable efficacy, safety, and immune rebalancing in atopic dermatitis.CRVS
Study update - Strong efficacy, safety, and immune modulation support Phase II trials for soquelitinib in atopic dermatitis.CRVS
Study result - Soquelitinib showed robust efficacy and safety, with $31.3M raised to fund operations into late 2026.CRVS
Q1 2025 - Soquelitinib advances with strong clinical data and a $52M cash runway into Q1 2026.CRVS
Q4 2024